CTLA4Ig: bridging the basic immunology with clinical application.

Published

Journal Article

After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.

Full Text

Duke Authors

Cited Authors

  • Bluestone, JA; St Clair, EW; Turka, LA

Published Date

  • March 2006

Published In

Volume / Issue

  • 24 / 3

Start / End Page

  • 233 - 238

PubMed ID

  • 16546089

Pubmed Central ID

  • 16546089

International Standard Serial Number (ISSN)

  • 1074-7613

Digital Object Identifier (DOI)

  • 10.1016/j.immuni.2006.03.001

Language

  • eng

Conference Location

  • United States